# Scholar Rock (SRRK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SRRK
## Company Profile
- Ticker: SRRK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 53.82 USD
- Market cap: 5353930141.84 USD
- Last updated: 2026-08-12
## Business Overview
### Myostatin Biology
Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.
### Apitegromab
Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.
### Additional Pipeline
Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.
## Why The Stock Is Moving

As of Aug 12, 2026, SRRK closed up 3.36% at $53.82. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA action on the apitegromab BLA by September 30, 2026.
- Potential U.S. launch of apitegromab immediately following approval.

## Recent News
- 2026-08-07 20:20 EST — [Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date](https://biopharmsignal.com/news/SRRK/scholar-rock-announces-fda-review-of-apitegromab-biologics-license-application-b-ba9f6662) — Source: Scholar Rock
- 2026-08-06 11:00 EST — [Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-second-quarter-2026-financial-results-and-recent-business-h-6dbccec0) — Source: Scholar Rock
- 2026-07-29 12:00 EST — [Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-9ad1248c) — Source: Scholar Rock
- 2026-07-20 12:00 EST — [Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)](https://biopharmsignal.com/news/SRRK/scholar-rock-provides-update-on-timing-of-committee-for-medicinal-products-for-h-018ed6e6) — Source: Scholar Rock
- 2026-07-17 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-f0ff2185) — Source: Scholar Rock